Genetic Engineering & Biotechnology News

OCT1 2012

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 77 of 89

Corporate Capabilities ADVERTORIAL OriGene Technologies O riGene Technologies was founded in 1996 as a research tool company fo- cused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. OriGene's mission, to prepare comprehensive sets of gene research tools and technology plat- forms, has enabled scientists to study complete biological pathways, thus facilitating a better understanding of biological processes and dis- ease regulation, including cancer and stem cell research. The comprehensive expression clone collection (now expanded to mouse and rat) is the core asset of OriGene. Upon this foundation, the company has prepared 17,000 overexpres- sion cell lysates, >7,000 purified recombinant human proteins (HEK293 expressed), and >5,000 highly characterized monoclonal anti- bodies sold under the TrueMAB™ brand name. Over the past few years, OriGene has strate- gically integrated multiple technologies through corporate acquisitions to create a whole-product solution for the life sciences market. Cytomyx (>150,000 high-quality human tissues collected under IRB protocol), Marligen Biosciences (nu- cleic acid purification and licensed Luminex® assay developer), and Blue Heron (Leader in gene synthesis services) have all been effectively united into one technology portfolio. The recent acquisition of ZSbio (a leading Chinese pathol- ogy company) marks the company's latest ven- ture and entry into the diagnostic testing market. OriGene, Your Gene Company 9620 Medical Center Drive, Suite 200 Rockville, MD 20850 Phone 888.267.4436 Website Date Founded 1996 Number of Employees 400 Markets Served 1) Molecular Biology: As "Your Gene Com- pany", OriGene has a broad portfolio of bio- logical reagents and services that are of value to both academic research and industry prod- uct development. Utilizing high-throughput technologies in molecular cloning, the hu- man cDNA collection is nearing completion with respect to the NCBI RefSeq curated da- tabase of unique human transcripts. Such a comprehensive portfolio of cDNA clones is of particular value to laboratories that wish to move their projects along quickly by pur- chasing "ready-made" clones and where time is of the essence in mission critical research. If not immediately available, OriGene's Blue Heron synthesis service can conveniently pro- vide any gene, any sequence, in any vector, with add-on services of codon-optimization and large-scale DNA purification. The cDNA clone sets can be used for high-throughput functional screening to identify novel players in biological processes. 2) Protein Assay and Antibodies: OriGene's 7,000 recombinant human proteins pro- duced in human cells are of high value to researchers that are interested in authentic structure. Proteins with correct post-transla- tional modifications (phosphorylation, glyco- sylation, etc.) are crucial for biologically rel- evant structure and functional studies. They are also ideal for assay development, small molecule interaction screening, or as antigens for antibody production. Taking full advantage of the successful pu- rification of these human proteins, OriGene has created manufacturing capacity to pro- duce over 300 fully validated monoclonal an- tibodies per month (TrueMAB). This grow- ing catalog of well over 5,000 antibodies is currently supplying leading researchers with highly specific antibodies directed against au- thentic human protein antigens with valida- tion assurances for critical applications such as Western, flow, IP, IF, IHC, ELISA and for multiplexed assays. 3) Diagnostic Tests: To address the unresolved challenges of antibody cross-reactivity, Ori- Gene has created a new generation of anti- bodies known as UltraMAB™ Antibodies. Each UltraMAB has been rigorously tested on OriGene's proprietary high-density 10K protein lysate microarray to validate and confirm its mono-specificity against human protein antigens. (See image for HER2 Ultra- MAB data.) 76 | October 1, 2012 | | Genetic Engineering & Biotechnology News Advancing Its World-Class Collection of cDNA Clones, Human Proteins, Antibodies, and Assays into the Diagnostics Arena This unmatched quality metric and novel approach to antibody validation is crucial for antibody-based applications, especially for diagnostic tests involving IHC and/or flow cytometry. The launch and expansion of the UltraMAB collection have been greatly ap- preciated by leading diagnostic partners and welcomed by many assay and companion-di- agnostics developers challenged by the issues of cross-reactivity. This places OriGene in a unique position to serve as the preeminent partner and collaborator for diagnostic anti- body development. Capabilities With the largest collections of full-length cDNA clones, human-cell produced purified proteins, TrueMAB antibodies and recently re- leased "mono-specific" UltraMAB antibodies, OriGene is now capable of utilizing its reagent toolbox in the craft of assay development for drug discovery and disease-based diagnostics. OriGene has created a 10K protein lysate mi- croarray in 2011, which is soon to be expanded to 15,000 overexpression protein lysates, which will significantly expand the company's capa- bilities for antibody validation. This product is ideal for testing antibody specificity, decoding of monoclonal antibodies (identifying target an- tigens), and for profiling auto-antibodies in pa- tient sera. Several key projects with these arrays are leading to new cancer diagnostic tests or are aimed at improving those already in use in the clinical setting. For more information, contact OriGene is committed to its mission to be "Your Gene Company", a high-quality supplier of gene- focused products to biomedical researchers. Q

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - OCT1 2012